Catumaxomab (English Wikipedia)

Analysis of information sources in references of the Wikipedia article "Catumaxomab" in English language version.

refsWebsite

Global rank English rank

7nih.gov

4^th place

4doi.org

2^nd place

4europa.eu

68^th place

117^th place

2web.archive.org

1^st place

1landesbioscience.com

low place

1semanticscholar.org

11^th place

8^th place

1fresenius.se

low place

1espacenet.com

800^th place

676^th place

1lifescience-online.com

low place

1neovii.com

low place

doi.org

Linke R, Klein A, Seimetz D (2010). "Catumaxomab: clinical development and future directions". mAbs. 2 (2): 129–36. doi:10.4161/mabs.2.2.11221. PMC 2840231. PMID 20190561.
Heiss MM, Murawa P, Koralewski P, Kutarska E, Kolesnik OO, Ivanchenko VV, et al. (November 2010). "The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: Results of a prospective randomized phase II/III trial". International Journal of Cancer. 127 (9): 2209–21. doi:10.1002/ijc.25423. PMC 2958458. PMID 20473913.
Lordick F, Ott K, Weitz J, Jäger D (September 2008). "The evolving role of catumaxomab in gastric cancer". Expert Opinion on Biological Therapy. 8 (9): 1407–15. doi:10.1517/14712598.8.9.1407. PMID 18694358. S2CID 73237824.
Ruf P, Gires O, Jäger M, Fellinger K, Atz J, Lindhofer H (August 2007). "Characterisation of the new EpCAM-specific antibody HO-3: implications for trifunctional antibody immunotherapy of cancer". British Journal of Cancer. 97 (3): 315–21. doi:10.1038/sj.bjc.6603881. PMC 2360319. PMID 17622246.

espacenet.com

worldwide.espacenet.com

EP 1315520, Lindhofer H, "Use of Trifunctional Bispecific and Trispecific Antibodies for the Treatment of Malignant Ascites", assigned to Trion Pharma GmbH

europa.eu

ema.europa.eu

"European Public Assessment Report for March 2009" (PDF). European Medicines Agency. March 2009.
"Removab: Withdrawal of the marketing authorisation in the European Union" (PDF). European Medicines Agency. 10 July 2017.
"Korjuny EPAR". European Medicines Agency (EMA). 17 October 2024. Retrieved 19 October 2024. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
"Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 14-17 October 2024". European Medicines Agency (EMA). 18 October 2024. Retrieved 21 October 2024.

fresenius.se

"Capital Market Day Fresenius Biotech: Fresenius concentrates biotechnology activities on antibody and innovative cell therapies". Fresenius SE. Archived from the original on 26 August 2010.

landesbioscience.com

Linke R, Klein A, Seimetz D (2010). "Catumaxomab: clinical development and future directions". mAbs. 2 (2): 129–36. doi:10.4161/mabs.2.2.11221. PMC 2840231. PMID 20190561.

lifescience-online.com

"TRION Pharma: Trifunctional Antibody Catumaxomab Kills Cancer Stem Cells". Archived from the original on 2011-07-13. Retrieved 2009-11-19.

neovii.com

"Neovii completes marketing authorisation withdrawal of Removab in the European Union". Neovii Biotech GmbH. 26 July 2017.

nih.gov

pubmed.ncbi.nlm.nih.gov

Linke R, Klein A, Seimetz D (2010). "Catumaxomab: clinical development and future directions". mAbs. 2 (2): 129–36. doi:10.4161/mabs.2.2.11221. PMC 2840231. PMID 20190561.
Heiss MM, Murawa P, Koralewski P, Kutarska E, Kolesnik OO, Ivanchenko VV, et al. (November 2010). "The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: Results of a prospective randomized phase II/III trial". International Journal of Cancer. 127 (9): 2209–21. doi:10.1002/ijc.25423. PMC 2958458. PMID 20473913.
Lordick F, Ott K, Weitz J, Jäger D (September 2008). "The evolving role of catumaxomab in gastric cancer". Expert Opinion on Biological Therapy. 8 (9): 1407–15. doi:10.1517/14712598.8.9.1407. PMID 18694358. S2CID 73237824.
Ruf P, Gires O, Jäger M, Fellinger K, Atz J, Lindhofer H (August 2007). "Characterisation of the new EpCAM-specific antibody HO-3: implications for trifunctional antibody immunotherapy of cancer". British Journal of Cancer. 97 (3): 315–21. doi:10.1038/sj.bjc.6603881. PMC 2360319. PMID 17622246.

ncbi.nlm.nih.gov

Linke R, Klein A, Seimetz D (2010). "Catumaxomab: clinical development and future directions". mAbs. 2 (2): 129–36. doi:10.4161/mabs.2.2.11221. PMC 2840231. PMID 20190561.
Heiss MM, Murawa P, Koralewski P, Kutarska E, Kolesnik OO, Ivanchenko VV, et al. (November 2010). "The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: Results of a prospective randomized phase II/III trial". International Journal of Cancer. 127 (9): 2209–21. doi:10.1002/ijc.25423. PMC 2958458. PMID 20473913.
Ruf P, Gires O, Jäger M, Fellinger K, Atz J, Lindhofer H (August 2007). "Characterisation of the new EpCAM-specific antibody HO-3: implications for trifunctional antibody immunotherapy of cancer". British Journal of Cancer. 97 (3): 315–21. doi:10.1038/sj.bjc.6603881. PMC 2360319. PMID 17622246.

semanticscholar.org

api.semanticscholar.org

Lordick F, Ott K, Weitz J, Jäger D (September 2008). "The evolving role of catumaxomab in gastric cancer". Expert Opinion on Biological Therapy. 8 (9): 1407–15. doi:10.1517/14712598.8.9.1407. PMID 18694358. S2CID 73237824.

web.archive.org

"Capital Market Day Fresenius Biotech: Fresenius concentrates biotechnology activities on antibody and innovative cell therapies". Fresenius SE. Archived from the original on 26 August 2010.
"TRION Pharma: Trifunctional Antibody Catumaxomab Kills Cancer Stem Cells". Archived from the original on 2011-07-13. Retrieved 2009-11-19.